To present the impact of treatments on health-related quality of life ( HRQoL ) from the double-blind , randomised phase III COMBI-d study that investigated the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600E/K-mutant metastatic melanoma .